Cargando…

Next frontier in tumor immunotherapy: macrophage-mediated immune evasion

Tumor-associated macrophages (TAMs), at the core of immunosuppressive cells and cytokines networks, play a crucial role in tumor immune evasion. Increasing evidences suggest that potential mechanisms of macrophage-mediated tumor immune escape imply interpretation and breakthrough to bottleneck of cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Yingqi, Chen, Tong, Hu, Rong, Zhu, Ruiyi, Li, Chujun, Ruan, Yingchen, Xie, Xiaoling, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501632/
https://www.ncbi.nlm.nih.gov/pubmed/34625124
http://dx.doi.org/10.1186/s40364-021-00327-3
_version_ 1784580725519941632
author Qiu, Yingqi
Chen, Tong
Hu, Rong
Zhu, Ruiyi
Li, Chujun
Ruan, Yingchen
Xie, Xiaoling
Li, Yuhua
author_facet Qiu, Yingqi
Chen, Tong
Hu, Rong
Zhu, Ruiyi
Li, Chujun
Ruan, Yingchen
Xie, Xiaoling
Li, Yuhua
author_sort Qiu, Yingqi
collection PubMed
description Tumor-associated macrophages (TAMs), at the core of immunosuppressive cells and cytokines networks, play a crucial role in tumor immune evasion. Increasing evidences suggest that potential mechanisms of macrophage-mediated tumor immune escape imply interpretation and breakthrough to bottleneck of current tumor immunotherapy. Therefore, it is pivotal to understand the interactions between macrophages and other immune cells and factors for enhancing existing anti-cancer treatments. In this review, we focus on the specific signaling pathways through which TAMs involve in tumor antigen recognition disorders, recruitment and function of immunosuppressive cells, secretion of immunosuppressive cytokines, crosstalk with immune checkpoints and formation of immune privileged sites. Furthermore, we summarize correlative pre-clinical and clinical studies to provide new ideas for immunotherapy. From our perspective, macrophage-targeted therapy is expected to be the next frontier of cancer immunotherapy.
format Online
Article
Text
id pubmed-8501632
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85016322021-10-20 Next frontier in tumor immunotherapy: macrophage-mediated immune evasion Qiu, Yingqi Chen, Tong Hu, Rong Zhu, Ruiyi Li, Chujun Ruan, Yingchen Xie, Xiaoling Li, Yuhua Biomark Res Review Tumor-associated macrophages (TAMs), at the core of immunosuppressive cells and cytokines networks, play a crucial role in tumor immune evasion. Increasing evidences suggest that potential mechanisms of macrophage-mediated tumor immune escape imply interpretation and breakthrough to bottleneck of current tumor immunotherapy. Therefore, it is pivotal to understand the interactions between macrophages and other immune cells and factors for enhancing existing anti-cancer treatments. In this review, we focus on the specific signaling pathways through which TAMs involve in tumor antigen recognition disorders, recruitment and function of immunosuppressive cells, secretion of immunosuppressive cytokines, crosstalk with immune checkpoints and formation of immune privileged sites. Furthermore, we summarize correlative pre-clinical and clinical studies to provide new ideas for immunotherapy. From our perspective, macrophage-targeted therapy is expected to be the next frontier of cancer immunotherapy. BioMed Central 2021-10-09 /pmc/articles/PMC8501632/ /pubmed/34625124 http://dx.doi.org/10.1186/s40364-021-00327-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Qiu, Yingqi
Chen, Tong
Hu, Rong
Zhu, Ruiyi
Li, Chujun
Ruan, Yingchen
Xie, Xiaoling
Li, Yuhua
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
title Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
title_full Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
title_fullStr Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
title_full_unstemmed Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
title_short Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
title_sort next frontier in tumor immunotherapy: macrophage-mediated immune evasion
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501632/
https://www.ncbi.nlm.nih.gov/pubmed/34625124
http://dx.doi.org/10.1186/s40364-021-00327-3
work_keys_str_mv AT qiuyingqi nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion
AT chentong nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion
AT hurong nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion
AT zhuruiyi nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion
AT lichujun nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion
AT ruanyingchen nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion
AT xiexiaoling nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion
AT liyuhua nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion